Clinical Report: GPR34 Expression in Microglia in Alzheimer’s Disease

Overview

This report examines the expression of GPR34 in microglia in human cases of Alzheimer's disease (AD). It highlights the consistent expression of GPR34 despite the presence of AD pathology, suggesting its potential role in microglial function and AD progression.

Background

Alzheimer’s disease is a leading cause of dementia, characterized by neurodegeneration and cognitive decline. Microglia, the resident immune cells of the central nervous system, play a crucial role in neuroinflammation and may influence AD pathology. Understanding the expression and function of specific microglial receptors, such as GPR34, is essential for developing targeted therapies.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• GPR34 is selectively expressed in microglia and is downregulated in aging brains.
• Deletion of GPR34 in transgenic AD models improves cognitive function and reduces neuroinflammation.
• GPR34 signaling may contribute to microglial phagocytosis of amyloid-β and tau proteins.
• Microglial responses to GPR34 signaling can vary depending on the pathological context.
• Current mouse models do not fully replicate human AD pathology, limiting translational insights.

Clinical Implications

The consistent expression of GPR34 in microglia suggests it may be a potential therapeutic target in Alzheimer's disease. Understanding its role in microglial function could inform strategies to modulate neuroinflammation and improve cognitive outcomes in AD patients.

Conclusion

GPR34 remains consistently expressed in microglia in Alzheimer's disease, indicating its potential significance in disease mechanisms and as a therapeutic target. Further research is needed to elucidate its precise role in AD pathology.

Related Resources & Content

1. Acta Neuropathologica — The Role of Microglia in Central Nervous System Disorders Across Development and Aging
2. Acta Neuropathologica — Analysis of Early Cellular Senescence in Alzheimer’s Disease Through Single Nuclear Transcriptomic Approaches
3. Acta Neuropathologica — Transcriptomic Analysis of Neuroimmune Cells in the Brain and Spinal Cord of Amyotrophic Lateral Sclerosis Patients
4. Acta Neuropathologica — Phosphorylated tau in the hippocampus of Alzheimer’s disease promotes degeneration of microglial cells
5. Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice - Jack - 2024 - Alzheimer's & Dementia: Translational Research & Clinical Interventions
6. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine
7. Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice - Jack - 2024 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
8. Lecanemab in Early Alzheimer’s Disease | New England Journal of Medicine